Strategic Collaborations SIGA Technologies actively partners with leading academic and biotech institutions such as Vanderbilt University and Calidi Biotherapeutics, presenting opportunities to offer advanced bioproducts, monoclonal antibodies, or biotherapeutic solutions that align with their innovative research efforts.

Emerging Disease Focus With core products targeting high-impact infectious diseases like smallpox and mpox, there is a strong demand for diagnostic, prophylactic, and therapeutic tools for organizations involved in biodefense, public health agencies, and healthcare providers focused on emerging infectious risks.

Government Contracting SIGA's collaborations with the Department of Defense and funding support suggest ongoing opportunities to supply advanced medical countermeasures, vaccines, or related technologies to government agencies concerned with biothreat preparedness.

Innovative Drug Development Development of Post-exposure Prophylaxis indications and monoclonal antibodies indicates a market for advanced pharmaceuticals, vaccines, and biotherapeutics, especially for health organizations and military sectors seeking cutting-edge bioproducts for infection prevention and treatment.

Regulatory & Compliance Readiness Addressing recent investigations into securities law violations highlights the importance of compliance and regulatory solutions, providing opportunities to support businesses in maintaining regulatory standards and navigating legal complexities in biotech product development and commercialization.